19:32 , Oct 5, 2018 |  BC Week In Review  |  Financial News

GW raises $345M follow-on

GW Pharmaceuticals plc (NASDAQ:GWPH) raised $345 million through the sale of 2.2 million ADSs at $158 in a follow-on underwritten by Goldman Sachs, Morgan Stanley and J.P. Morgan. The offering includes a 285,000 share overallotment...
19:09 , Oct 3, 2018 |  BC Extra  |  Financial News

GW, Epizyme, Kala price follow-ons

GW Pharmaceuticals plc (NASDAQ:GWPH), Epizyme Inc. (NASDAQ:EPZM) and Kala Pharmaceuticals Inc. (NASDAQ:KALA) each priced follow-ons late Tuesday, raising a total of $437 million. GW raised $300 million through the sale of 1.9 million ADSs at $158...
17:58 , Sep 28, 2018 |  BC Week In Review  |  Company News

GW to launch Epidiolex in U.S. following DEA reschedule

GW Pharmaceuticals plc (NASDAQ:GWPH) said the U.S. Drug Enforcement Agency has rescheduled Epidiolex cannabidiol to schedule V, the lowest restriction classification, from a schedule I, clearing the way for GW to launch the drug in...
22:29 , Sep 21, 2018 |  BioCentury  |  Emerging Company Profile

Aprinoia tackles tau

Aprinoia Therapeutics Inc. is developing a pipeline targeting tauopathies that includes diagnostic imaging tracers, mAbs specific to pathologic tau and small molecules that bind to tau rather than dissociate tau aggregates. “We are going to develop...
18:55 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Zynerba refocusing on CBD gel following failed patch readout

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) said it will focus on developing ZYN002 after single and multiple doses of several formulations of ZYN001 failed to achieve target blood levels of 5-15 ng/mL of tetrahydrocannabinol (THC) in a...
18:49 , Jul 5, 2018 |  BC Extra  |  Clinical News

Zynerba refocusing on CBD gel following failed patch readout

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) said it will focus on developing ZYN002 after single and multiple doses of several formulations of ZYN001 failed to achieve target blood levels of 5-15 ng/mL of tetrahydrocannabinol (THC) in a...
14:55 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

FDA approves GW’s Epidiolex, first marijuana-derived drug

FDA approved Epidiolex cannabidiol from GW Pharmaceuticals plc (NASDAQ:GWPH) on June 25, marking the first U.S. approval of a marijuana-derived purified substance, according to the agency. Epidiolex is indicated to treat seizures associated with Lennox-Gastaut...
22:02 , Jun 25, 2018 |  BC Extra  |  Company News

FDA approves GW’s Epidiolex, first marijuana-derived drug

FDA approved Epidiolex cannabidiol from GW Pharmaceuticals plc (NASDAQ:GWPH), marking the first U.S. approval of a marijuana-derived purified substance, according to the agency. Epidiolex is indicated to treat seizures associated with Lennox-Gastaut syndrome and Dravet...
22:09 , Jan 5, 2018 |  BC Week In Review  |  Company News

Zynerba discontinuing ZYN002 and ZYN001 for pain indications

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) said it will discontinue development of ZYN002 to treat osteoarthritis (OA) pain and ZYN001 to treat fibromyalgia and general peripheral neuropathic pain to focus on rare and near-rare neurological and psychiatric...
22:09 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

Zynerba reports additional data for epilepsy candidate ZYN002

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) reported data from 171 patients with confirmed refractory epilepsy with focal seizures with or without secondary generalization who completed the Phase II STAR 1 trial and were enrolled in the STAR...